{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.53","value":"0.71"},{"groupId":"OG001","spread":"1.55","value":"1.88"},{"groupId":"OG002","spread":"1.25","value":"1.98"},{"groupId":"OG003","spread":"0","value":"1.80"},{"groupId":"OG004","spread":"4.45","value":"5.97"},{"groupId":"OG005","spread":"0","value":"5.02"},{"groupId":"OG006","spread":".43","value":"7.95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"11"}],"units":"Participants"}],"description":"Maximum serum concentration (Cmax) of sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with refractory solid tumors or leukemias.","dispersionType":"Standard Error","groups":[{"description":"Patients receive oral sorafenib 105 mg/m\\^2 every 12 hours.","id":"OG000","title":"Part A: Refractory Solid Tumors: BAY 43-9006 105 mg/m^2"},{"description":"Patients receive oral sorafenib 150 mg/m\\^2 every 12 hours.","id":"OG001","title":"Part A: Refractory Solid Tumors: BAY 43-9006 150 mg/m^2"},{"description":"Patients receive oral sorafenib 200 mg/m\\^2 every 12 hours.","id":"OG002","title":"Part A: Refractory Solid Tumors: BAY 43-9006 200 mg/m^2"},{"description":"Patients receive oral sorafenib 250 mg/m\\^2 every 12 hours.","id":"OG003","title":"Part A: Refractory Solid Tumors: BAY 43-9006 250 mg/m^2"},{"description":"Patients receive oral sorafenib 150 mg/m\\^2 every 12 hours.","id":"OG004","title":"Part B: Refractory Leukemia: BAY 43-9006 150 mg/m^2"},{"description":"Patients receive oral sorafenib 200 mg/m\\^2 every 12 hours.","id":"OG005","title":"Part B: Refractory Leukemia: BAY 43-9006 200 mg/m^2"},{"description":"Patients receive oral sorafenib 200 mg/m\\^2 every 12 hours.","id":"OG006","title":"PK Cohort Expanded: BAY 43-9006 200 mg/m^2"}],"paramType":"MEAN","populationDescription":"Data was not collected for patients from Part A:130 mg/m\\^2","reportingStatus":"POSTED","timeFrame":"During cycle 1 or cycle 2 after at least 14 consecutive days of sorafenib administration Pre-dose, 0.5, 1, 2, 3, 5, 8 hours post dose","title":"Maximum Serum Concentration (Cmax) of Sorafenib","type":"PRIMARY","unitOfMeasure":"µg/ml"}